In this randomized clinical trial, offering hyperbaric oxygen therapy to women with late local toxic effects was not effective for reducing pain, but was effective for reducing fibrosis. https://ja.ma/441K7Pf
JAMA Oncology
Book and Periodical Publishing
Chicago, Illinois 33,307 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaoncology
External link for JAMA Oncology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 2015
- Specialties
- Oncology
Updates
-
Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months. https://ja.ma/49N5F3m
-
-
Most viewed in the last 7 days from JAMA Oncology: Can a new 18-gene urinary test for high-grade prostate cancer improve PSA screening outcomes relative to existing biomarker tests? https://ja.ma/3xUOpvU
-
-
In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). https://ja.ma/3xRYlGt
-
-
Most viewed in the last 7 days from JAMA Oncology: Do young breast cancer survivors have a high risk of developing a second primary breast cancer? https://ja.ma/3Jo3rwx
-
-
Postoperative pelvic irradiation combined with concurrent chemotherapy using hypofractionated IMRT with 40 Gy in 16 fractions was safe and well-tolerated in women with cervical cancer, finds nonrandomized controlled trial. https://ja.ma/44hAEmR
-
-
Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. https://ja.ma/3Jp2oN2
-
-
In solid tumors from patients with bone metastasis, MW032 and denosumab were biosimilar in efficacy, population pharmacokinetics, and safety profile. https://ja.ma/3xBtVrI
-
-
ICI-chemotherapy did not improve survival compared with ICI alone in older adults with previously untreated advanced NSCLC, but increased the incidence of grade 3 and higher immune-related adverse events. https://ja.ma/3W6Cl4Q
-
-
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer. https://ja.ma/49XGAmB
Policy Priorities in Cancer Care for Transgender People
jamanetwork.com